Overview

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months

Status:
Active, not recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

To date, the majority of clinical trials on checkpoint inhibitors have tested these agents as monotherapy, and the next logical step is to evaluate rational therapeutic associations. The aim of the NiCOL study is to assess the safety of nivolumab in association with chemoradiation therapy and to gain initial insight into its efficacy in association with the current standard of care, including chemoradiation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Institut Curie

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Cisplatin
Nivolumab